Resumen
Background and Purpose: In preclinical studies, cannabidiol (CBD) mitigates fear memories by facilitating their extinction or interfering with their generalization and reconsolidation. The brain regions and mechanisms underlying these effects, and their temporal window, are still poorly understood. Here, we have investigated related questions in the dorsal hippocampus (DH) during contextual fear consolidation. Experimental Approach: Adult male Wistar rats received CBD (10–30 pmol) intra-DH immediately, 1 or 3 hr after fear conditioning. Effects of CBD on consolidation were inferred behaviourally and by analysing expression of the activity-regulated, cytoskeleton-associated (Arc) protein. The contribution of anandamide, CB1, CB2, 5-HT1A, A2A, and PPARγ receptors was also assessed. Key Results: CBD impaired memory consolidation when given immediately or 1 hr after fear conditioning, but not after 3 hr. Expression of Arc protein in DH was reduced by systemic CBD treatment in both cases. Immediately after fear conditioning, CBD effects were abolished by CB1 or CB2 receptor blockade, partly reduced by 5-HT1A or A2A antagonism, and remained unchanged after antagonism of PPARγ receptors. One hour after fear conditioning, CBD effects were prevented only by PPARγ receptor antagonism. Also, inhibition of fatty acid amide hydrolase by URB597, impaired memory consolidation when infused immediately, but not 1 hr after fear conditioning. Conclusions and Implications: CBD disrupts memory consolidation up to 1 hr after fear conditioning, allowing an extended window of opportunity to mitigate aversive memories after their acquisition. Our results suggest time-dependent participation of anandamide, CB1, CB2 and PPARγ receptors in the DH, during this process.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 945-957 |
Número de páginas | 13 |
Publicación | British Journal of Pharmacology |
Volumen | 177 |
N.º | 4 |
DOI | |
Estado | Published - feb. 1 2020 |
Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:Our study was supported by Brazilian grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2017/24304-0), Fundação Araucária (convênio 006/2017), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 409615/2016-1), and CAPES (Finance code 001). FAPESP, Fundação Araucária, CNPq, and CAPES had no further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. We thank Dr. Ana Paula S. Dornellas for helping us to conduct the western blotting study; Dr. Joice Maria da Cunha from the Department of Pharmacology, Federal University of Parana for kindly donating WAY100635; Dr. Rui Daniel S. Prediger from the Department of Pharmacology, Federal University of Santa Catarina for kindly donating ZM241385; and Phytoplant for kindly donating cannabidiol.
Funding Information:
Our study was supported by Brazilian grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2017/24304‐0), Fundação Araucária (convênio 006/2017), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 409615/2016‐1), and CAPES (Finance code 001). FAPESP, Fundação Araucária, CNPq, and CAPES had no further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. We thank Dr. Ana Paula S. Dornellas for helping us to conduct the western blotting study; Dr. Joice Maria da Cunha from the Department of Pharmacology, Federal University of Parana for kindly donating WAY100635; Dr. Rui Daniel S. Prediger from the Department of Pharmacology, Federal University of Santa Catarina for kindly donating ZM241385; and Phytoplant for kindly donating cannabidiol.
Publisher Copyright:
© 2019 The British Pharmacological Society
ASJC Scopus Subject Areas
- Pharmacology
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't